Bitter-Tasting Drugs Can Control Appetite Hormones GDF15 and GLP-1 Through Taste Receptors in the Gut

Bitter compounds regulate GDF15 and GLP-1 release from human gut epithelial cells through specific TAS2R subtypes and the unfolded protein response, with TAS2R polymorphisms predicting therapeutic responsiveness.

Placebo-controlled, double-blind, randomized crossover study of oral hydroxychloroquine in healthy volunteers (plasma GDF15, ghrelin, hunger scores). Ex vivo stimulation of primary jejunal crypts from patients with obesity. Immunofluorescence colocalization. TAS2R antagonist (GIV3727) blocking studies. TAS2R4/43 genotyping for polymorphism analysis.

This reveals a completely new mechanism for controlling appetite — bitter taste receptors in the gut that regulate two powerful satiety signals simultaneously. Since genetic variations predict who responds, this could enable personalized obesity treatment based on taste receptor genetics, offering an alternative to injectable GLP-1 drugs.

This study connects three hot research areas: GLP-1 biology, GDF15 as a satiety signal, and taste receptor pharmacology. The finding that oral bitter compounds can boost both GDF15 and GLP-1 through gut taste receptors suggests a potential oral, non-peptide alternative to injectable GLP-1 agonists. The pharmacogenomic angle (taste receptor polymorphisms predicting response) adds a precision medicine dimension rarely seen in obesity research.

Small crossover study in healthy volunteers — larger obesity trials needed. Ex vivo gut tissue experiments may not fully reflect in vivo responses. The bitter compounds tested have other pharmacological effects beyond taste receptors. Not all bitter compounds had the same direction of effect on GDF15. Long-term efficacy and tolerability of bitter-based appetite suppression unknown.